Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34790
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18240/20438 (89%)
Visitors : 5479820      Online Users : 875
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    CNU IR > Offices > 456 >  Item 310902800/34790
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34790


    Title: A novel quinoline derivative, DFIQ, sensitizes NSCLC cells to ferroptosis by promoting oxidative stress accompanied by autophagic dysfunction and mitochondrial damage
    Authors: Bow, Yung-Ding
    Ko, Ching-Chung
    Chang, Wen-Tsan
    Chou, Sih-Yan
    Hung, Chun-Tzu
    Huang, Jau-Ling
    Tseng, Chih-Hua
    Chen, Yeh-Long
    Li, Ruei-Nian
    Chiu, Chien-Chih
    Contributors: Kaohsiung Med Univ, Coll Life Sci, PhD Program Life Sci
    Chi Mei Med Ctr, Dept Med Imaging
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Kaohsiung Med Univ Hosp, Dept Surg, Div Gen & Digest Surg
    Kaohsiung Med Univ, Coll Med, Sch Med, Dept Surg
    Kaohsiung Med Univ, Dept Biotechnol
    Chang Jung Christian Univ, Coll Hlth Sci, Dept Biosci Technol
    Kaohsiung Med Univ, Coll Pharm, Drug Dev & Value Creat Res Ctr, Sch Pharm
    Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Drug Dev & Value Creat Res Ctr, Dept Med & Appl Chem,Dept Med Res
    Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol
    Kaohsiung Med Univ Hosp, Dept Med Res
    Natl Sun Yat Sen Univ, Dept Biol Sci
    Kaohsiung Med Univ, Ctr Canc Res
    Natl Appl Res Labs, Natl Lab Anim Ctr
    Keywords: NSCLC
    Ferroptosis
    Chemotherapy
    Camptothecin derivative
    Mitochondrial dysfunction
    Autophagic flux disruption
    ROS imbalance
    Date: 2023
    Issue Date: 2024-12-25 11:03:28 (UTC+8)
    Publisher: BMC
    Abstract: BackgroundThe development of nonapoptotic programmed cell death inducers as anticancer agents has emerged as a cancer therapy field. Ferroptosis, ferrous ion-driven programmed cell death that is induced by redox imbalance and dysfunctional reactive oxygen species (ROS) clearance, is triggered during sorafenib and PD-1/PD-L1 immunotherapy. DFIQ, a quinoline derivative, promotes apoptosis by disrupting autophagic flux and promoting ROS accumulation. Our pilot experiments suggest that DFIQ participates in ferroptosis sensitization. Thus, in this study, we aimed to reveal the mechanisms of DFIQ in ferroptosis sensitization and evaluate the clinical potential of DFIQ.MethodsWe treated the non-small cell lung cancer (NSCLC) cell lines H1299, A549, and H460 with the ferroptosis inducer (FI) DFIQ and analyzed viability, protein expression, ROS generation, and fluorescence staining at different time points. Colocalization analysis was performed with ImageJ.ResultsDFIQ sensitized cells to FIs such as erastin and RSL3, resulting in a decrease in IC50 of at least 0.5-fold. Measurement of ROS accumulation to explore the underlying mechanism indicated that DFIQ and FIs treatment promoted ROS accumulation and SOD1/SOD2 switching. Mitochondria, known ROS sources, produced high ROS levels during DFIQ/FI treatment. RSL3 treatment promoted mitochondrial damage and mitophagy, an autophagy-associated mitochondrial recycling system, and cotreatment with DFIQ induced accumulation of mitochondrial proteins, which indicated disruption of mitophagic flux. Thus, autophagic flux was measured in cells cotreated with DFIQ. DFIQ treatment was found to disrupt autophagic flux, leading to accumulation of damaged mitochondria and eventually inducing ferroptosis. Furthermore, the influence of DFIQ on the effects of clinical FIs, such as sorafenib, was evaluated, and DFIQ was discovered to sensitize NSCLC cells to sorafenib and promote ferroptosis.ConclusionsThis study indicates that DFIQ not only promotes NSCLC apoptosis but also sensitizes cells to ferroptosis by disrupting autophagic flux, leading to accumulation of dysfunctional mitochondria and thus to ferroptosis. Ferroptosis is a novel therapeutic target in cancer therapy. DFIQ shows the potential to enhance the effects of FIs in NSCLC and act as a potential therapeutic adjuvant in ferroptosis-mediated therapy.
    Relation: Cancer Cell International, v.23, n.1, Article 171
    Appears in Collections:[Offices] 456

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML5View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback